Yahoo
NasdaqGS - Delayed Quote USD

Caribou Biosciences, Inc. (CRBU)

1.5700 -0.0900 (-5.42%)
At close: June 25 at 4:00:00 PM EDT
1.6072 +0.0372 (+2.37%)
Pre-Market: 4:00:19 AM EDT
Trade CRBU on Coinbase
Chart Range Bar
Loading chart for CRBU
  • Previous Close 1.6600
  • Open 1.6800
  • Bid 1.1900 x 200
  • Ask 2.0000 x 200
  • Day's Range 1.5600 - 1.6899
  • 52 Week Range 1.2200 - 3.5350
  • Volume 1,609,166
  • Avg. Volume 1,649,004
  • Market Cap (intraday) 155.714M
  • Beta (5Y Monthly) 2.33
  • PE Ratio (TTM) --
  • EPS (TTM) -1.4200
  • Earnings Date (est.) May 7, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 12.00

Caribou Biosciences, Inc. operates as a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It offers a genome-editing platform based on novel CRISPR hybrid RNA-DNA genome-editing technology that enables precise genome editing of allogeneic cell therapies. The company develops Vispacabtagene Regedleucel, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

cariboubio.com

97

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 6/25/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CRBU
1.26%
S&P 500 (^GSPC)
7.48%

1-Year Return

CRBU
10.56%
S&P 500 (^GSPC)
20.77%

3-Year Return

CRBU
63.74%
S&P 500 (^GSPC)
69.20%

5-Year Return

CRBU
91.10%
S&P 500 (^GSPC)
71.88%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 2.4M
Earnings -25.09M

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-30M
-20M
-10M
0

Analyst Insights

View More

Analyst Price Targets

4.00
12.00 Average
1.5700 Current
32.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 5/11/2026
Analyst HC Wainwright & Co.
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 9 -> 11

Statistics

View More

Valuation Measures

Annual
As of 6/25/2026
  • Market Cap

    155.71M

  • Enterprise Value

    65.03M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    13.20

  • Price/Book (mrq)

    1.53

  • Enterprise Value/Revenue

    5.80

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -34.69%

  • Return on Equity (ttm)

    -83.46%

  • Revenue (ttm)

    11.2M

  • Net Income Avi to Common (ttm)

    -133.22M

  • Diluted EPS (ttm)

    -1.4200

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    117.63M

  • Total Debt/Equity (mrq)

    26.41%

  • Levered Free Cash Flow (ttm)

    -63.51M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

1.5700 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: